Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Seattle Genetics
 More »

  • Takeover Targets: Who Is First on the List?
    ... biotech firms most likely to be acquired in 2013. Seattle Genetics Focus: Developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. ...
    9-24-2013
  • Bayer, Broad on Five-Year Mission to Search for Novel Cancer...
    Also, in June, Seattle Genetics awarded worldwide rights for its auristatin-based antibody-drug conjugate technology to Bayer HealthCare with the aim of producing new cancer ...
    9-10-2013
  • As Big Deals Resurface, Who's Next to the Altar?
    ... BioMarin and Medivation also turned up last month in a Jim Cramer list of takeover targets that included Seattle Genetics. He cited the company's antibody-drug conjugate licensing ...
    9-9-2013
  • Top 25 Biotech Companies of 2013
    ... shares * price $18.09) % Change: 70.2% Position on 2012 List: Not ranked #19. Seattle Genetics 2013 Market Cap: $4.390 billion (5/2: 121,265,608 shares * price $36.20) 2012 ...
    7-15-2013
  • Bayer, Seattle Genetics Launch Up to $520M ADC Collaboration
    Seattle Genetics awarded worldwide rights for its auristatin-based antibody-drug conjugate technology, with antibodies to several oncology targets, to Bayer HealthCare, in a ...
    6-25-2013
  • Merck, BMS Immunotherapy Data Whets Clinical Oncology Appetite...
    Oncology meeting, the drug giants were in good company-Peregrine Pharmaceuticals and Seattle Genetics were among the smaller biopharmas to report promising clinical data this week. ...
    6-3-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Financial terms not disclosed. Roche (Ventana Medical Systems) and Seattle Genetics and Takeda Pharmaceutical (Millennium: The Takeda Oncology Company) Agreement announced April ...
    5-9-2013
  • BMS Partners Again with Ambrx, in Up-to-$112M-and-Up ADC Collaboration
    Ambrx and BMS are among companies looking to develop ADCs: The list includes Roche (Genentech)'s Kadcyla, approved in February for breast cancer indications, and Seattle Genetics' ...
    5-3-2013
  • OBT Joins Boehringer Ingelheim in Cancer Drug Collaboration
    with Seattle Genetics, Medarex (since acquired by Bristol-Myers Squibb), Amgen, Biosite (now Alere), and BioWa, as well as development alliances with Sanofi and Menarini. ...
    4-29-2013
  • GEN | Biolinks
    ... Foundation Ireland Science Industries Switzerland SCILOG Seahorse Bioscience Seattle Genetics Selexis Sheffield Bio-Science Shimadzu Siga Technologies Sigma-Aldrich Signature ...
  • Meeting the Bioassay Challenge
    ... and Mary Hu, Ph.D., director, bioassay development and process analytics, Seattle Genetics. "Two curves that are highly precise can often be shown to be different when ...
    3-15-2013
  • Top 20 Venture Capital Firms
    ... Frazier Healthcare Ventures Location(s): Seattle and Menlo Park, CA Fund size and status: ... Delenex Therapeutics, Good Start Genetics, Imagen Biotech, Itero ...
    12-17-2012
  • GEN Reports on Growing Interest in Antibody-Drug Conjugates
    it. Other companies in the GEN article include Ambryx Biotechnology, Spirogen, ADC Therapeutics, Mersana Therapeutics, Seattle Genetics, Roche/Genentech, ImmunoGen, and Pfizer.
    12-10-2012
  • Cancer Research Firms Eye ADCs to Extend Portfolios
    ... Spirogen "Spirogen has developed its own novel, very potent payload and a novel mechanism of action. It's one to watch," Chew says. "Genentech and Seattle Genetics are each ...
    12-1-2012
  • EC Conditionally Sanctions Lymphoma Treatment
    The EC granted conditional approval for Seattle Genetics and Millennium's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) for two indications: the treatment of adult ...
    10-31-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll